Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

NCT04899349 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2024-10-09 · Breast cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns”	–	Registry record, Novartis Pharmaceuticals

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PIK3CA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision